Mark J. Gergen

2023 - Poseida Therapeutics

In 2023, Mark J. Gergen earned a total compensation of $3.8M as Chief Executive Officer, President and Chairman at Poseida Therapeutics, a 13% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$336,420
Option Awards$1,413,936
Salary$611,667
Stock Awards$1,442,285
Other$13,710
Total$3,818,018

Gergen received $1.4M in stock awards, accounting for 38% of the total pay in 2023.

Gergen also received $336.4K in non-equity incentive plan, $1.4M in option awards, $611.7K in salary and $13.7K in other compensation.

Rankings

In 2023, Mark J. Gergen's compensation ranked 199th out of 2,912 executives tracked by ExecPay. In other words, Gergen earned more than 93.2% of executives.

ClassificationRankingPercentile
All
199
out of 2,912
93rd
Division
Manufacturing
108
out of 1,602
93rd
Major group
Chemicals And Allied Products
71
out of 901
92nd
Industry group
Drugs
70
out of 864
92nd
Industry
Biological Products, Except Diagnostic Substances
26
out of 211
88th
Source: SEC filing on April 25, 2024.

Gergen's colleagues

We found two more compensation records of executives who worked with Mark J. Gergen at Poseida Therapeutics in 2023.

2023

Kristin Yarema

Poseida Therapeutics

President, Cell Therapy

2023

Brent Warner

Poseida Therapeutics

President, Gene Therapy

News

You may also like